TCT-ASTCT-CIBMTR 2022 - 2022 Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
Apr 23 - Apr 26, 2022 | Salt Lake CityUTUS
LARVOL is not affiliated with 2022 Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR and all trademarks, logos, and brand names are property of their respective owners
Showing 120 abstracts linked to Trials
Cost-Effectiveness of Axicabtagene Ciloleucel As Second-Line Therapy for Patients Large B-Cell Lymphoma (LBCL) in the United States
Incidence of Secondary Malignancies after Total Body Irradiation-Based Allogeneic HSCT in Children with ALL – Long-Term Follow-up from the Prospective ALL-SCT 2003 Trial
The Effect of Post-Transplant Bendamustine on Immune Reconstitution in Young Patients Undergoing T-Cell Replete Haploidentical Bone Marrow Transplantation: A Phase Ia/Ib Clinical Trial
Two-Year (yr) Follow-up (FU) of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)
Mgta-145 + Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study
CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma
Preliminary Data from a Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning Is Well-Tolerated, Facilitates Chimerism and Clearance of Minimal Residual Disease in Older Adults with MDS/AML Undergoing Allogeneic HCT
[PRE-RECORD] Updated Results of Cartitude-2: Ciltacabtagene Autoleucel (cilta-cel), a B-Cell Maturation Antigen (BCMA)–Directed Chimeric Antigen Receptor T Cell (CAR-T) Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma (MM) after 1–3 Prior Lines of Therapy
Phase I/II Study Reducing Post-Transplantation Cyclophosphamide Dosing after Myeloablative HLA-Haploidentical Bone Marrow Transplantation
Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial
Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial
High Efficacy and Low Toxicity of MB-106, a Third Generation CD20 Targeted CAR-T for Treatment of Relapsed/Refractory B-NHL and CLL
Mutation Analysis in Patients with High-Risk Myelodysplastic Syndrome Receiving Allogeneic Hematopoietic Cell Transplantation Based on Biological Donor Availability: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Study 1102.
Anakinra Targeting Cytokine Release Syndrome (CRS) Associated with Chimeric Antigen Receptor T Cell (CAR-T) Therapies
Favourable Outcome after Treosulfan Based Conditioning in Patients Undergoing an Allogeneic Hematopoietic Cell Transplantation (alloHCT) for the Treatment of Acute Myleloid Leukaemia (AML): A Subgroup Analysis of the Randomized Phase III MC-Fludt.14/L Trial